Join Us at CTAD26: Advancing Alzheimer’s Disease Clinical Research Together
The 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference will take place in Boston, USA, on November 16–19, 2026. Since 2008, CTAD has served as a global forum dedicated exclusively to Alzheimer’s disease clinical research, bringing together investigators, clinicians, industry scientists, and regulatory experts committed to advancing the field.
CTAD is designed as a focused scientific meeting. All sessions are held in a single main ballroom, ensuring that the entire community shares the same presentations and discussions. This unified format fosters a collective scientific experience, encourages in-depth dialogue, and creates meaningful interactions across disciplines.
At CTAD25 in San Diego, more than 2,850 international experts gathered to discuss emerging data and evolving strategies in Alzheimer’s disease research. The program included high-level symposia and roundtables, 74 oral communications, and over 400 posters spanning translational science and late-stage clinical development. Discussions addressed disease-modifying therapies, gene- and cell-based approaches, vaccines, digital tools, and multimodal interventions—reflecting the breadth and dynamism of the field.
CTAD26 will continue this tradition of rigorous scientific exchange. The conference offers an opportunity to engage with key opinion leaders, clinical trialists, regulatory representatives, and multidisciplinary research teams, while gaining insight into the latest advances shaping prevention and treatment strategies.
CTAD is also aligned with the Journal of Prevention of Alzheimer’s Disease (JPAD), the conference’s official journal (2024 Impact Factor: 7.8), which extends the reach of the research presented at the meeting to the broader scientific community.
We warmly invite you to join us in Boston for CTAD26. Together, through open dialogue and shared scientific commitment, we can continue to advance Alzheimer’s disease research and improve outcomes for patients worldwide.